Time for TED thread on MAM.
I hold so this is probably a blatant ramp, but take a look.
The share is now off its low of 11.5p.
Although many got burnt in thr over hype a few years ago, I think the company
Is now well positioned for advancement.
Management have said that more Nucleopure machine sales are in the pipeline.

Have a listen to TEDs CE here, http://www.wallstreetreporter.com/profiles/TepnelLifeSciences.html

Guardian
Finally, it's worth keeping an eye on Tepnel Life Sciences. Market professionals reckon the AIM-listed DNA technology group has been overlooked in the past month and could now enjoy a good run. They note directors recently bought stock and point out that Tepnel's acquisition of Orchid Diagnostics should significantly boost the company's revenue stream and help it reach a much broader customer base. Tepnel closed 0.5p higher at 13p last night.

Sunday Telegraph
Tepnel is close to completing a second acquisition, having just bought the DNA-testing division of Orchid BioSciences, which allows it to enter the US market and increase the customer base for its DNA technology. Buy at 14.25p, the paper says.
regards
dave

I'm always happy to leave something for the next person, but I think I left too much ha! ha! Well done to all holders that's some premium as at 21st Jan.
2517

Espirito Santo Execution Noble Buy 1,627.00 1,470.00 1,150.00 1,650.00 Upgrades